ChromaDex Corporation (CDXC)
NASDAQ: CDXC · IEX Real-Time Price · USD
2.775
+0.015 (0.54%)
At close: Jul 19, 2024, 4:00 PM
2.840
+0.065 (2.34%)
Pre-market: Jul 22, 2024, 9:04 AM EDT
ChromaDex Employees
ChromaDex had 106 employees as of December 31, 2023. The number of employees decreased by 7 or -6.19% compared to the previous year.
Employees
106
Change (1Y)
-7
Growth (1Y)
-6.19%
Revenue / Employee
$784,594
Profits / Employee
-$33,283
Market Cap
209.62M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| The Beauty Health Company | 881 |
| Nature's Sunshine Products | 814 |
| Forafric Global | 600 |
| Whole Earth Brands | 590 |
| Lifeway Foods | 289 |
| Alico | 194 |
| FitLife Brands | 37 |
CDXC News
- 6 days ago - ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August - Business Wire
- 21 days ago - ChromaDex to Join Russell 2000® Index - Business Wire
- 4 weeks ago - Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD) - Business Wire
- 5 weeks ago - ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC) - Business Wire
- 6 weeks ago - ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT) - Business Wire
- 6 weeks ago - ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Tuesday, June 11, 2024 - Business Wire
- 2 months ago - ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 - Business Wire
- 2 months ago - ChromaDex's Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award - Business Wire